Russia Direct Investment Fund and Hualan Biotechnology reached an agreement

The Russian Direct Investment Fund (RDIF, Sovereign Wealth Fund of the Russian Federation) and Hualan Biovaccine Co.
, Ltd.
(a subsidiary of Hualan Bioengineering Co.
, Ltd.
, a leading biopharmaceutical company in China, and the largest influenza vaccine manufacturer in China) announced an agreement.
The world's first registered vaccine against coronavirus, "Sputnik V", will be produced in China with more than 100 million doses per year
.

The production volume enables more than 50 million people to be vaccinated
.

The "Sputnik V" vaccine has been registered in 60 countries with a total population of 3 billion
.

The vaccine is based on a mature and well-researched human adenovirus vector platform.
Two different vectors are used for two vaccination during the vaccination process, which has a longer-lasting immunity than a vaccine that uses the same administration mechanism for two vaccination
.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) said:

"The cooperation agreement with China's leading vaccine manufacturer Hualan Biovaccine Co.
, Ltd.
will enable us to meaningfully expand the production capacity of "Sputnik V"
.

The Russian Direct Investment Fund (RDIF) was established in 2011, mainly to make equity investments in Russian companies together with leading foreign financial and strategic investors
.